Hongxing Pan

机构：Jiangsu Provincial Center for Disease Control and Prevention, Nanjing Medical University · ORCID：0000-0002-3791-1241

发表论文 92 篇 · 总被引 4222 次 · h-index 25

代表论文

• Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study (2024 · Emerging Microbes & Infections · 被引 10)
• A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3–17 years (2025 · npj Vaccines · 被引 8)
• Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study (2024 · Expert Review of Vaccines · 被引 7)
• Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial (2025 · Human Vaccines & Immunotherapeutics · 被引 6)
• Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial (2024 · The Lancet Infectious Diseases · 被引 5)
• Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial (2025 · Nature Communications · 被引 4)